Verona Pharma ADR Logo
US9250501064
A2N39N
VRNA

Verona Pharma ADR

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 68,68 € (-24,78 %). Medianen er 67,11 € (-26,50 %).

Køb
  9
Behold
  5
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Verona Pharma shareholders approve $10 billion acquisition by Merck, Nasdaq trading to be suspended

    Verona Pharma shareholders authorized Merck’s $10 billion takeover at $107 per American Depositary Share, with completion expected after a High Court hearing on October 7. Nasdaq trading in Verona Pharma shares will be suspended on the same day and the deadline for depositary share payments is October 8. The approval follows encouraging Phase 3 ENHANCE results for Verona Pharma’s COPD drug Ohtuvayre, noted as the first novel inhaled COPD mechanism in over two decades. » Mere på finance.yahoo.com


  • Merck takeover drives Verona Pharma to all-time high

    Verona Pharma’s ADRs rose to a record high of 106.45 USD, giving the company a market capitalization of around 9.17 billion USD. Merck plans to acquire the company at 107 USD per ADS as part of a transaction worth about 10 billion USD, expected to close in the fourth quarter of 2025 and to be financed with investment-grade bonds. Analysts subsequently adjusted valuations and cut several ratings on Verona Pharma, while the stock shows a one-year return of roughly 257% and a high liquidity ratio (Current Ratio 10.71). » Mere på de.investing.com


  • Verona Pharma reaches record high ahead of takeover offer from Merck

    The ADRs of Verona Pharma rose to an all-time high of $105.86, driven by strong price performance (up 306.73% in 12 months) and solid financial metrics. Merck has announced it will acquire Verona for $107 per ADS in a roughly $10 billion transaction, expected to close in Q4 2025. Several analysts adjusted their ratings on Verona after the takeover announcement—some downgraded the stock, while TD Cowen raised its price target to $107. » Mere på de.investing.com


  • Merck highlights dividend reliability and growth amid acquisition of Verona Pharma

    Merck & Co., Inc. is recognized for its strong dividend history and recent strategic moves, including the $10 billion acquisition of Verona Pharma to diversify beyond Keytruda. The company reported solid first quarter results, driven by new medicines and vaccines, and continues to focus on innovation and long-term value creation. Merck currently offers a quarterly dividend of $0.81 per share with a yield of 3.82% as of July 26. » Mere på finance.yahoo.com


  • Verona Pharma hits record high after takeover announcement by Merck

    Shares of Verona Pharma reached an all-time high after Merck announced an acquisition worth around $10 billion. The transaction is expected to close in the fourth quarter of 2025 and offers a 23% premium over the previous closing price. Analysts downgraded Verona Pharma following the announcement but see benefits for shareholders due to Merck's resources. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Verona Pharma ADR en omsætning på 63,75 mio. € og et nettoresultat på 7,37 mio. €
(EUR) juni 2025
YoY
Omsætning 63,75 mio. -
Bruttofortjeneste 60,81 mio. -
Nettoresultat 7,37 mio. -
EBITDA 8,47 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
65,91 mia. €
Antal aktier
679,83 mio.
Højeste/laveste i 52 uger
96,97 € - 28,19 €
Udbytte Nej
Beta
0,05
P/E (PE Ratio)
-63,64
PEG (PEG Ratio)
-7,02
K/I (PB Ratio)
41,96
P/S (PS Ratio)
2.152,23

Virksomhedsprofil

Verona Pharma plc er et biofarmaceutisk selskab i klinisk fase, der fokuserer på udvikling og kommercialisering af behandlinger til respiratoriske sygdomme med uopfyldte medicinske behov. Selskabets produktkandidat er ensifentrin, en inhaleret og dobbelt hæmmer af phosphodiesterase (PDE) 3- og PDE4-enzymerne, som virker både som bronkodilatator og som antiinflammatorisk middel i én enkelt forbindelse. Stoffet er i fase 3-kliniske forsøg til behandling af kronisk obstruktiv lungesygdom, astma og cystisk fibrose. Selskabet udvikler ensifentrin i tre formuleringer, herunder forstøver, tørpulverinhalator og trykdoseret inhalator med doseringsmåler. Verona Pharma plc blev stiftet i 2005 og har hovedkontor i London, Storbritannien.

Navn
Verona Pharma ADR
CEO
David S. Zaccardelli
Hjemsted London,
Storbritannien
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
28.04.2017
Medarbejdere 209

Tickersymboler

Børs Symbol
NASDAQ
VRNA
Frankfurt
I9SA.F
Düsseldorf
I9SA.DU
Hamburg
I9SA.HM
München
I9SA.MU
🍪

Parqet  bruger cookies. Læs mere